As a leading diagnostic company, Oxford Immunotec’s mission is to raise TB awareness in the hopes of eradicating this terrible disease by providing an accurate diagnostic test. We partner with survivors to share their personal stories and work hard to be a leader in the fight against TB.
TB numbers from the WHO
There are many facts about tuberculosis (TB) that would startle most people. TB is often thought of as a problem of the past, or a problem faced in other countries. In fact, TB continues to affect those worldwide. Consider the following…
It is estimated that 60 million lives were saved through TB diagnosis and treatment between 2000 and 20191
People became sick with TB
In 2019, 10 million people became sick with TB1
People died from active TB disease
In 2019, approximately 1.4 million people died from the disease worldwide1
People living with LTBI
About 25% of the world’s population has LTBI1
People will be killed by TB between 2015-2030
28,000,000 people will die of TB in a 15 year period unless global control efforts are stepped up1
End TB Strategy by 2035
The World Health Organization END TB Strategy aims to end the global epidemic of TB by 20356
Progress towards 2020 End TB milestones is falling short (WHO annual report)1
The WHO’s annual report on the status of global efforts to End TB notes that, at the present trajectory, most WHO regions and individual countries will fall significantly short of the End TB 2020 milestones:
Reduction in TB incidence rate
Reduction in TB deaths
Areas on track to meet the 2020 milestones for both incidence rates and deaths include the WHO European Region, as well as Kenya, Lesotho, Myanmar, the Russian Federation, South Africa, Tanzania and Zimbabwe
A new, more effective vaccine could help reduce TB rates; however, the most promising vaccine (M72/AS01E) is not expected to be available until 2028 at the earliest, which is very close to the End TB target year of 2030
In 2014 the World Health Organization outlined the END TB Strategy, which details ambitious targets with the goal of ending the global epidemic of TB by 2035. It also sets interim milestones for 2020, 2025 and 2030, so that progress towards these targets can be easily tracked.
The End TB strategy:6
Vision: A world free of TB. Zero deaths, disease and suffering due to TB
Goal: End the global tuberculosis epidemic
95% reduction by 2035 in number of TB deaths compared with 2015
90% reduction by 2035 in TB incidence rate compared with 2015
Zero TB-affected families facing catastrophic costs due to TB by 2035
Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American ThoracicSociety/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. Published online December 8, 2016:ciw694. doi:10.1093/cid/ciw694
Wong SH, Gao Q, Tsoi KKF, et al. Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax. 2016;71:64–72.
Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, IGRA Expert Committee, Centers for Disease Control and Prevention (CDC). Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection – United States, 2010. MMWR Recomm Rep. 2010; 59(RR-5:1-25.
WHO End TB Strategy. World Health Organization. Published September 8, 2015. Accessed November 12, 2020.
Wrighton-Smith P, Sneed L, Humphrey F, Tao X, Bernacki E. Screening health care workers with interferon-γ release assay versus tuberculin skin test: Impact on costs and adherence to testing (the SWITCH study). J Occupational & Environmental Med. 2012;54(7):806-815
GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology & Hepatology. 2020;5(1):17-30
Lai CC, Tan CK, et al. Diagnostic performance of whole-blood interferon-γ assay and enzyme-linked immunospot assay for active tuberculosis. J Microbiol Immunol Infect. 2011 Oct;44(5):406-7. doi: 10.1016/j.jmii.2011.07.002. Epub 2011 Sep 8.
Redelman-Sidi G, Sepkowitz KA. Interferon-gamma release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med 2013; 188:422-431. 2012/12/25. DOI: 10.1164/rccm.201209-1621CI.
Exposure to TB. Centers for Disease Control and Prevention. CDC Exposure to TB. Published March 21, 2016. Accessed January 8, 2020.
TB Risk Factors. Centers for Disease Control and Prevention. CDC TB Risk Factors. Published March 18, 2016. Accessed January 8, 2020.
Huebner R, Schein M, Bass J. The tuberculin skin test. Clin Infect Dis. 1993;968-975.
Treatment for TB Disease. Centers for Disease Control and Prevention. CDC Treatment for TB Disease. Published April 5, 2016. Accessed January 8, 2020.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.